Skip to main content

Advertisement

SpringerLink
Log in

Role of Nutrition and Muscle in Cirrhosis

  • Liver (J Bajaj, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Most widely recognized complications in cirrhotic patients include ascites, hepatic encephalopathy, variceal bleeding, kidney dysfunction, and hepatocellular carcinoma; however, malnutrition and muscle wasting (sarcopenia) constitute common complications which negatively impact survival, quality of life, and response to stressors, such as infection and surgery in patients with cirrhosis. Despite the important role that malnutrition and sarcopenia play in the prognosis of patients with cirrhosis, they are frequently overlooked, in part because nutritional assessment can be a difficult task in patients with cirrhosis due to fluid retention and/or overweight. Moreover, patients with cirrhosis may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of “sarcopenic obesity.” In addition, muscle depletion is characterized by both a reduction in muscle size and increased proportion of intermuscular and intramuscular fat-denominated “myosteatosis.” Sarcopenia in cirrhotic patients has been associated with increased mortality, sepsis complications, hyperammonemia, overt hepatic encephalopathy, and increased length of stay after liver transplantation. Muscularity assessment with cross-sectional imaging studies has become an attractive index of nutritional status evaluation in cirrhosis, as sarcopenia reflects a chronic detriment in general physical condition, rather than acute severity of the liver disease. In this review, we discuss the current diagnostic methods to evaluate malnutrition and muscle abnormalities in cirrhosis and also analyze the current knowledge regarding incidence and clinical impact of malnutrition and muscle abnormalities in cirrhosis and their impact after liver transplantation. We also discuss existing and potential novel therapeutic strategies for malnutrition in cirrhosis, emphasizing the recognition of sarcopenia in cirrhosis in an effort to improve survival and reduce morbidity related to cirrhosis. Finally, we analyze new studies including sarcopenia with the MELD score that seems to allow better prediction of mortality among cirrhotic patients waiting for liver transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012;16:95–131.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;10:166–73. The initial paper describing the association of sarcopenia measured by CT and increase mortality in patients with cirrhosis.

    Article  PubMed  Google Scholar 

  3. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.

    Article  PubMed  Google Scholar 

  4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.

    Article  CAS  PubMed  Google Scholar 

  5. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.

    Article  PubMed  Google Scholar 

  6. Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CMM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016; In press. This paper describes the frequency of sarcopenic obesity and myosteatosis and its association with increase mortality in patients with cirrhosis.

  7. Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract. 2013;28:15–29. This review describes nutritional assessment tools and general principles in the nutritional support of patients with advanced liver disease.

    Article  PubMed  Google Scholar 

  8. O’Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology. 2008;134:1729–40.

    Article  PubMed  Google Scholar 

  9. Montano-Loza AJ. Skeletal muscle abnormalities and outcomes after liver transplantation. Liver Transpl. 2014;20:1293–5.

    Article  PubMed  Google Scholar 

  10. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr. 2005;81:903–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol a-Biol. 2005;60:324–33.

    Article  Google Scholar 

  13. Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 2007;102:919–25.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol. 2013;78:525–32. This Korean sarcopenic obesity study showed that HOMA-IR and 25[OH]D levels were independently associated with sarcopenic obesity in men, while HOMA-IR and hsCRP were significant factors predicting sarcopenic obesity in women.

    Article  CAS  Google Scholar 

  15. Plevak DJ, Dicecco SR, Wiesner RH, Porayko MK, Wahlstrom HE, Janzow DJ, et al. Nutritional support for liver-transplantation—identifying caloric and protein-requirements. Mayo Clin Proc. 1994;69:225–30.

    Article  CAS  PubMed  Google Scholar 

  16. Montano-Loza AJ. New concepts in liver cirrhosis: clinical significance of sarcopenia in cirrhotic patients. Minerva Gastroenterol Dietol. 2013;59:173–86.

    CAS  PubMed  Google Scholar 

  17. Quigley EMM. Gastrointestinal dysfunction in liver disease and portal hypertension—gut-liver interactions revisited. Digest Dis Sci. 1996;41:557–61.

    Article  CAS  PubMed  Google Scholar 

  18. Kalaitzakis E, Bosaeus I, Ohman L, Bjornsson E. Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditures. Am J Clin Nutr. 2007;85:808–15.

    CAS  PubMed  Google Scholar 

  19. Lemoine O, Marchant A, Degroote D, Azar C, Goldman M, Deviere J. Role of defective monocyte interleukin-10 release in tumor-necrosis-factor-alpha overproduction in alcoholic cirrhosis. Hepatology. 1995;22:1436–9.

    Article  CAS  Google Scholar 

  20. Madden AM, Bradbury W, Morgan MY. Taste perception in cirrhosis: its relationship to circulating micronutrients and food preferences. Hepatology. 1997;26:40–8.

    Article  CAS  PubMed  Google Scholar 

  21. Bergheim I, Parlesak A, Dierks C, Bode JC, Bode C. Nutritional deficiencies in German middle-class male alcohol consumers: relation to dietary intake and severity of liver disease. Eur J Clin Nutr. 2003;57:431–8.

    Article  CAS  PubMed  Google Scholar 

  22. Montano-Loza AJ. Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr. 2014;17:219–25.

    Article  Google Scholar 

  23. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.

    Article  CAS  PubMed  Google Scholar 

  24. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003;58:911–6.

    Article  Google Scholar 

  25. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Elliott JM, Kerry R, Flynn T, Parrish TB. Content not quantity is a better measure of muscle degeneration in whiplash. Manual Ther. 2013;18:578–82.

    Article  Google Scholar 

  27. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010;21:543–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. World J Gastroenterol. 2015;21:7637–47. This review describes the role of sarcopenia in determining the prognosis of patients with cirrhosis. It also discusses the role of sarcopenia alone or in combination with MELD in the assessment of prognosis of patients with cirrhosis.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013;47:861–70.

    Article  PubMed  Google Scholar 

  30. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transplant. 2012;18:1209–16.

    Article  Google Scholar 

  31. Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl. 2014;20:640–8.

    Article  PubMed  Google Scholar 

  32. Cruz RJ, Dew MA, Myaskovsky L, Goodpaster B, Fox K, Fontes P, et al. Objective radiologic assessment of body composition in patients with end-stage liver disease: going beyond the BMI. Transplantation. 2013;95:617–22.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Masuda T, Shirabe K, Ikegami T, Harimoto N, Yoshizumi T, Soejima Y, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transplant. 2014;20:401–7. This study showed that sarcopenia is an independent predictor of mortality and sepsis after living donor transplantation. They also showed that the occurrence of post operative sepsis decreased in patients with sarcopenia after routine application of early enteral nutrition.

    Article  Google Scholar 

  34. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013;19:1396-402.

  36. Shen W, Punyanitya M, Wang ZM, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333–8.

    Article  PubMed  Google Scholar 

  37. Kim TY, Kim MY, Sohn JH, Kim SM, Ryu JA, Lim S, et al. Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites. J Korean Med Sci. 2014;29:1253–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014;60:1151–7. In this study transversal psoas muscle thickness/height on CT at the level of the umbilicus was an objective marker of sarcopenia was predictive of mortality in cirrhotic patients. This was independent of the MELD and MELD-Na scores.

    Article  PubMed  Google Scholar 

  39. Beneke R, Neuerburg J, Bohndorf K. Muscle cross-section measurement by magnetic resonance-imaging. Eur J Appl Physiol O. 1991;63:424–9.

    Article  CAS  Google Scholar 

  40. Parry SM, El-Ansary D, Cartwright MS, Sarwal A, Berney S, Koopman R, et al. Ultrasonography in the intensive care setting can be used to detect changes in the quality and quantity of muscle and is related to muscle strength and function. J Crit Care. 2015;30:1151.e9–1151.e14.

    Article  Google Scholar 

  41. Horber FF, Thomi F, Casez JP, Fonteille J, Jaeger P. Impact of hydration status on body composition as measured by dual energy X-ray absorptiometry in normal volunteers and patients on haemodialysis. Br J Radiol. 1992;65:895–900.

    Article  CAS  PubMed  Google Scholar 

  42. Pirlich M, Schutz T, Spachos T, Ertl S, Weiss ML, Lochs H, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology. 2000;32:1208–15.

    Article  CAS  PubMed  Google Scholar 

  43. Madden AM, Morgan MY. The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients. Nutrition. 1997;13:40–5.

    Article  CAS  PubMed  Google Scholar 

  44. Fiore P, Merli M, Andreoli A, De Lorenzo A, Masini A, Ciuffa L, et al. A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients. Clin Nutr. 1999;18:349–51.

    Article  CAS  PubMed  Google Scholar 

  45. Selberg O, Selberg D. Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur J Appl Physiol. 2002;86:509–16.

    Article  CAS  PubMed  Google Scholar 

  46. Toshikuni N, Arisawa T, Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol. 2014;20:7286–97.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Singal AK, Kamath PS, Francisco Ziller N, DiCecco S, Shoreibah M, Kremers W, et al. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013;26:788–94.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Baker JP, Detsky AS, Wesson DE, Wolman SL, Stewart S, Whitewell J, et al. Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med. 1982;306:969–72.

    Article  CAS  PubMed  Google Scholar 

  49. Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation. 1994;57:469–72.

    Article  CAS  PubMed  Google Scholar 

  50. Hirsch S, Bunout D, Delamaza P, Iturriaga H, Petermann M, Icazar G, et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. Jpen-Parenter Enter. 1993;17:119–24.

    Article  CAS  Google Scholar 

  51. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21:113–7.

    Article  PubMed  Google Scholar 

  52. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40:423–9.

    Article  PubMed  Google Scholar 

  53. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol a-Biol. 2006;61:1059–64.

    Article  Google Scholar 

  54. Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, et al. Six minute walk test to assess functional capacity in chronic liver disease patients. World J Gastroenterol. 2007;13:3996–4001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16:1373–8.

    Article  PubMed  Google Scholar 

  56. Glass C, Hipskind P, Tsien C, Malin SK, Kasumov T, Shah SN, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. J Appl Physiol. 2013;114:559–65. In this study, patients with cirrhosis low respiratory quotient were accompanied by low muscle mass. This indicated a decompensated metabolic state that should be managed by improved nutritional support to improve muscle mass.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Mowat NAG, Edwards CRW, Fisher R, Mcneilly AS, Green JRB, Dawson AM. Hypothalamic-pituitary-gonadal function in men with cirrhosis of liver. Gut. 1976;17:345–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303:E983–993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kovarik M, Muthny T, Sispera L, Holecek M. The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle. J Physiol Biochem. 2012;68:385–95.

    Article  CAS  PubMed  Google Scholar 

  60. Changani KK, Jalan R, Cox IJ, Ala-Korpela M, Bhakoo K, Taylor-Robinson SD, et al. Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy. Gut. 2001;49:557–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Montanari A, Simoni I, Vallisa D, Trifiro A, Colla R, Abbiati R, et al. Free amino acids in plasma and skeletal muscle of patients with liver cirrhosis. Hepatology. 1988;8:1034–9.

    Article  CAS  PubMed  Google Scholar 

  62. Montano-Loza AJ, Duarte-Rojo A, Bhanji R, Rose C. Cirrhotic patients with sarcopenia and sarcopenic-obesity have an increased risk of hyperammonemia and hepatic encephalopathy. Am J Gastroenterol. 2015;110:S875–5.

  63. Glass D, Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann Ny Acad Sci. 2010;1211:25–36.

    Article  PubMed  Google Scholar 

  64. Ruegg MA, Glass DJ. Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol. 2011;51:373–95.

    Article  CAS  Google Scholar 

  65. Dickinson JM, Fry CS, Drummond MJ, Gundermann DM, Walker DK, Glynn EL, et al. Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids. J Nutr. 2011;141:856–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Drummond MJ, Bell JA, Fujita S, Dreyer HC, Glynn EL, Volpi E, et al. Amino acids are necessary for the insulin-induced activation of mTOR/S6K1 signaling and protein synthesis in healthy and insulin resistant human skeletal muscle. Clin Nutr. 2008;27:447–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Drummond MJ, Glynn EL, Fry CS, Timmerman KL, Volpi E, Rasmussen BB. An increase in essential amino acid availability upregulates amino acid transporter expression in human skeletal muscle. Am J Physiol-Endoc M. 2010;298:E1011–8.

    CAS  Google Scholar 

  68. Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroentero. 2014;20:8061–71.

    Article  Google Scholar 

  69. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003;9:12–8.

    Article  PubMed  Google Scholar 

  70. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One. 2013;8, e51926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. DiMartini A, Cruz RJ, Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. Liver Transplant. 2013;19:1172–80.

    Article  Google Scholar 

  73. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JXQ, et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015;6:e102. In this study, MELD sarcopenia (defined by L3 skeletal muscle index) was calculated combining MELD score and sarcopenia. MELD-sarcopenia was associated with improved prediction of mortality in patients with cirrhosis, primarily in patients with low MELD score.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Norman K, Kirchner H, Lochs H, Pirlich M. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol. 2006;12:3380–5.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–50.

    Article  CAS  PubMed  Google Scholar 

  76. Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193–9. In this study, sarcopenia was associated with increased mortality in patients with cirrhosis and branched chain amino acid supplementation improved survival in sarcopenic patients.

    Article  PubMed  Google Scholar 

  77. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Brit J Nutr. 2006;96:895–901.

    Article  CAS  PubMed  Google Scholar 

  78. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8:979–85.

    Article  PubMed  Google Scholar 

  79. Montano-Loza AJ, Duarte-Rojo A, Rose CF. Sarcopenia and myosteatosis increase the risk of hepatic encephalopathy in cirrhotic patients. Hepatology. 2014;60:384a–5a.

    Google Scholar 

  80. Donaghy A, Ross R, Wicks C, Hughes SC, Holly J, Gimson A, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology. 1997;113:1617–22.

    Article  CAS  PubMed  Google Scholar 

  81. Moller S, Becker U, Gronbaek M, Juul A, Winkler K, Skakkebaek NE. Short-term effect of recombinant human growth-hormone in patients with alcoholic cirrhosis. J Hepatol. 1994;21:710–7.

    Article  CAS  PubMed  Google Scholar 

  82. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroen Hepatol. 2012;27:430–41.

    Article  CAS  Google Scholar 

  83. Dasarathy S, McCullough AJ, Muc S, Schneyer A, Bennett CD, Dodig M, et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol. 2011;54:915–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Fry CS, Drummond MJ, Glynn EL, Dickinson JM, Gundermann DM, Timmerman KL, et al. Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet Muscle. 2011;1:1–11.

    Article  Google Scholar 

  85. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinkes DL, et al. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab. 2008;294:E392–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Bonetto A, Penna F, Minero VG, Reffo P, Costamagna D, Bonelli G, et al. Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-alpha. Amino Acids. 2011;40:585–94.

    Article  CAS  PubMed  Google Scholar 

  87. Teran JC, Mullen KD, Mccullough AJ. Glutamine—a conditionally essential amino-acid in cirrhosis. Am J Clin Nutr. 1995;62:897–900.

    CAS  PubMed  Google Scholar 

  88. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino-acid treatment in chronic hepatic-encephalopathy—a randomized double-blind casein-controlled trial. J Hepatol. 1990;11:92–101.

    Article  CAS  PubMed  Google Scholar 

  89. Mcghee A, Henderson JM, Millikan WJ, Bleier JC, Vogel R, Kassouny M, et al. Comparison of the effects of hepatic-aid and a casein modular diet on encephalopathy, plasma amino-acids, and nitrogen-balance in cirrhotic-patients. Ann Surg. 1983;197:288–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, et al. Comparison of dietary-protein with an oral, branched-chain enriched amino-acid supplement in chronic portal-systemic encephalopathy—a randomized controlled trial. Hepatology. 1984;4:279–87.

    Article  CAS  PubMed  Google Scholar 

  91. Christie ML, Sack DM, Pomposelli J, Horst D. Enriched branched-chain amino-acid formula versus a casein-based supplement in the treatment of cirrhosis. Jpen-Parenter Enter. 1985;9:671–8.

    Article  CAS  Google Scholar 

  92. Swart GR, Vandenberg JWO, Vanvuure JK, Rietveld T, Wattimena DL, Frenkel M. Minimum protein-requirements in liver-cirrhosis determined by nitrogen-balance measurements at 3 levels of protein-intake. Clin Nutr. 1989;8:329–36.

    Article  CAS  PubMed  Google Scholar 

  93. Egberts EH, Schomerus H, Hamster W, Jurgens P. Branched-chain amino-acids in the treatment of latent portosystemic encephalopathy—a double-blind placebo-controlled crossover study. Gastroenterology. 1985;88:887–95.

    CAS  PubMed  Google Scholar 

  94. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.

    Article  CAS  PubMed  Google Scholar 

  95. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006;35:204–14.

    CAS  PubMed  Google Scholar 

  96. Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology 2016. In press.

  97. Hayashi F, Matsumoto Y, Momoki C, Yuikawa M, Okada G, Hamakawa E, et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res. 2013;43:1264–75.

    Article  PubMed  Google Scholar 

  98. Wilborn CD, Taylor LW, Greenwood M, Kreider RB, Willoughby DS. Effects of different intensities of resistance exercise on regulators of myogenesis. J Strength Cond Res. 2009;23:2179–87.

    Article  PubMed  Google Scholar 

  99. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13:1549–56. This study found that skeletal muscle depletion was closely involved with posttransplant mortality in patients undergoing living donor liver transplantation. Perioperative nutritional therapy significantly improved overall survival in cirrhotic patients with skeletal muscle depletion.

    Article  CAS  PubMed  Google Scholar 

  100. Yamauchi M, Takeda K, Sakamoto K, Ohata M, Toda G. Effect of oral branched chain amino acid supplementation in the late evening on the nutritional state of patients with liver cirrhosis. Hepatol Res. 2001;21:199–204.

    Article  CAS  PubMed  Google Scholar 

  101. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106:1081–8.

    Article  CAS  PubMed  Google Scholar 

  102. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25:85–93. This study demonstrated that some cirrhotic patients have reversal of sarcopenia after transjugular intrahepatic portosystemic stents, and this fining was associated with better survival.

    Article  PubMed  Google Scholar 

  103. Roman E, Torrades MT, Nadal MJ, Cardenas G, Nieto JC, Vidal S, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci. 2014;59:1966–75.

    Article  CAS  PubMed  Google Scholar 

  104. Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1920–1926 e1922. This prospective controlled pilot trial showed that 8 weeks of supervised aerobic exercise training led to increase in peak exercise oxygen uptake and muscle mass and reduced fatigue in patients with cirrhosis.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Division of Gastroenterology and Liver Unit, University of Alberta Hospital, Zeidler Ledcor Centre, 130 University Campus, Edmonton, AB, T6G 2X8, Canada

    Ragesh B. Thandassery MD DM & Aldo J. Montano-Loza MD, MSc, PhD

Authors
  1. Ragesh B. Thandassery MD DM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aldo J. Montano-Loza MD, MSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aldo J. Montano-Loza MD, MSc, PhD.

Ethics declarations

Conflict of interest

Ragesh B. Thandassery and Aldo J. Montano-Loza declare that they have no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thandassery, R.B., Montano-Loza, A.J. Role of Nutrition and Muscle in Cirrhosis. Curr Treat Options Gastro 14, 257–273 (2016). https://doi.org/10.1007/s11938-016-0093-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-016-0093-z

Keywords

Search

Navigation